Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P. De Remigis A, et al. Among authors: slovin sf. Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28. Int J Cancer. 2015. PMID: 24832153 Free PMC article.
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Antonarakis ES, et al. Among authors: slovin sf. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. doi: 10.1007/s00280-011-1759-9. Epub 2011 Oct 22. Cancer Chemother Pharmacol. 2012. PMID: 22020316 Free PMC article. Clinical Trial.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. McNeel DG, et al. Among authors: slovin sf. J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031820 Free PMC article.
Prostate Cancer National Summit's Call to Action.
Heath EI, Nanus DM, Slovin S, Strand C, Higano C, Simons VH, Johnson C, Kyriakopoulos CE, Reichert ZR, Lory S, George DJ, Mucci LA, Marcus JD, Trendel JA, Bock CH. Heath EI, et al. Clin Genitourin Cancer. 2019 Jun;17(3):161-168. doi: 10.1016/j.clgc.2019.04.002. Epub 2019 Apr 16. Clin Genitourin Cancer. 2019. PMID: 31085057 No abstract available.
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.
Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Reis BS, et al. Clin Cancer Res. 2013 Nov 15;19(22):6112-25. doi: 10.1158/1078-0432.CCR-12-3580. Epub 2013 Sep 30. Clin Cancer Res. 2013. PMID: 24081977
Harnessing T-lymphocytes for human cancer immunotherapy.
Hirshaut Y, Slovin SF. Hirshaut Y, et al. Among authors: slovin sf. Cancer. 1985 Sep 15;56(6):1366-73. doi: 10.1002/1097-0142(19850915)56:6<1366::aid-cncr2820560625>3.0.co;2-a. Cancer. 1985. PMID: 3896456 Review.
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. McKay RR, et al. Among authors: slovin sf. J Clin Oncol. 2016 Jun 1;34(16):1913-20. doi: 10.1200/JCO.2015.65.3154. Epub 2016 Apr 4. J Clin Oncol. 2016. PMID: 27044933 Free PMC article. Clinical Trial.
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ. McHugh D, et al. Among authors: slovin sf. Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6. Invest New Drugs. 2019. PMID: 30725389 Free PMC article. Clinical Trial.
175 results